Helix BioPharma (TSE:HBP)
TSX:HBP
HBP Stock Chart & Stats
C$2.40
-C$0.03(-3.23%)
At close: 4:00 PM EST
C$2.40
-C$0.03(-3.23%)
Day’s Range― - ―
52-Week RangeC$0.77 - C$5.40
Previous CloseN/A
Volume518.00
Average Volume (3M)13.00K
Market Cap
C$139.01M
Enterprise ValueC$139.34M
Total Cash (Recent Filing)C$31.00K
Total Debt (Recent Filing)C$359.00K
Price to Earnings (P/E)―
Beta1.98
Next Earnings
Jun 17, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding76,378,100
10 Day Avg. Volume29,165
30 Day Avg. Volume13,000
Financial Highlights & Ratios
PEG Ratio0.21
Price to Book (P/B)3.83
Price to Sales (P/S)0.00
P/FCF Ratio-15.56
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage / Equity CushionVery low debt relative to equity materially reduces near-term solvency risk and preserves strategic optionality. With a tangible equity base (~$15.4M) and minimal leverage, management can pursue R&D or partner deals without immediate creditor pressure, lengthening funding flexibility while pursuing clinical milestones.
Focused R&D, Asset-centric Business ModelA concentrated asset-development model aligns costs and capabilities to core value drivers: advancing clinical assets. This reduces commercial execution burden, enables clear capital allocation by program, and makes the company an attractive licensing or partner candidate—structural positives for a small biotech over months to years.
Improving Loss Trend / Cost DisciplineA declining loss trajectory versus prior years implies management has implemented durable cost controls or program prioritization. Sustained improvement can extend runway, reduce near-term financing needs, and increase the probability that the company can fund key development milestones or secure non-dilutive partnerships.
Bears Say
No Revenue / Pre-commercial OperationsAbsence of commercial revenue means the business fundamentally depends on capital markets, partnerships, or milestone payments. Without an operating revenue base, long-term sustainability hinges on successful clinical outcomes or financings, increasing execution and funding risk for investors over the medium term.
Persistent Negative Free Cash FlowSustained negative free cash flow signals ongoing cash burn that must be covered by financing or partners. That structural cash deficit increases dilution or refinancing risk, constrains strategic choices, and elevates the importance of milestone delivery or external funding to avoid disrupting development timelines.
Historically Volatile Balance SheetPrior episodes of negative equity indicate susceptibility to capital structure stress and prior reliance on dilutive financings. Historical volatility complicates long-term planning, may limit access to non-dilutive debt, and raises governance and investor confidence risks if future financing is required under adverse terms.
Helix BioPharma News
HBP FAQ
What was Helix BioPharma’s price range in the past 12 months?
Helix BioPharma lowest stock price was C$0.77 and its highest was C$5.40 in the past 12 months.
What is Helix BioPharma’s market cap?
Helix BioPharma’s market cap is C$139.01M.
When is Helix BioPharma’s upcoming earnings report date?
Helix BioPharma’s upcoming earnings report date is Jun 17, 2026 which is in 69 days.
How were Helix BioPharma’s earnings last quarter?
Helix BioPharma released its earnings results on Mar 16, 2026. The company reported -C$0.009 earnings per share for the quarter, missing the consensus estimate of N/A by -C$0.009.
Is Helix BioPharma overvalued?
According to Wall Street analysts Helix BioPharma’s price is currently Overvalued.
Does Helix BioPharma pay dividends?
Helix BioPharma does not currently pay dividends.
What is Helix BioPharma’s EPS estimate?
Helix BioPharma’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Helix BioPharma have?
Helix BioPharma has 76,378,100 shares outstanding.
What happened to Helix BioPharma’s price movement after its last earnings report?
Helix BioPharma reported an EPS of -C$0.009 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 2.793%.
Which hedge fund is a major shareholder of Helix BioPharma?
Currently, no hedge funds are holding shares in TSE:HBP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Helix BioPharma
Helix BioPharma Corp. operates as an immune-oncology company in Canada. It is developing L-DOS47 for the treatment of non-small cell lung cancer; and V-DOS47 that targets the vascular epithelial growth factor receptor 2. Helix BioPharma Corp. has collaboration agreements with Moffitt Cancer Center to investigate the pharmacodynamics of L-DOS47 and determine the benefits of combining L-DOS47 with immune checkpoint inhibitors; and with ProMab Biotechnologies, Inc. to develop novel antibody and chimeric antigen receptor T-cell therapy to treat multiple myeloma, as well as a license agreements with Xisle Pharma Ventures Trust and National Research of Council Canada. The company is headquartered in Richmond Hill, Canada.
Technical Analysis
Satellos Bioscience
―
Arch Biopartners
―
Medicenna Therapeutics Corp
―
ME Therapeutics Holdings, Inc.
―
Onco-Innovations Ltd.
―
Options Prices
Currently, No data available
---